Pharmacovigilance in India: PVPI & the Role of CDSCO

 

Introduction: India's Growing Commitment to Drug Safety

India is the third-largest pharmaceutical industry in the world by volume — producing medicines consumed by patients across every continent. With that scale of production comes an enormous responsibility: ensuring that every drug that reaches an Indian or international patient is continuously monitored for safety throughout its market life. Yet for many years, India's post-marketing pharmacovigilance system lagged significantly behind those of more mature regulatory markets like the US and EU.

That has changed substantially over the past decade. India now has a functioning national pharmacovigilance programme, a network of hundreds of Adverse Drug Reaction Monitoring Centres, and a regulatory framework that is increasingly aligned with international standards. For students who have completed Clinical Research Courses in Pune and are considering a specialisation in drug safety, understanding India's pharmacovigilance infrastructure — how it is structured, how it operates, and where it is heading — is both professionally essential and genuinely fascinating.

The Pharmacovigilance Programme of India (PvPI): Origins and Purpose

The Pharmacovigilance Programme of India was formally launched in July 2010 under the aegis of the Central Drugs Standard Control Organisation (CDSCO), with the Indian Pharmacopoeia Commission (IPC) in Ghaziabad designated as the National Coordination Centre (NCC). The programme was established with four primary objectives:

•         To monitor adverse drug reactions occurring in the Indian population

•         To create awareness among healthcare professionals about the importance of ADR reporting

•         To contribute Indian safety data to the WHO global pharmacovigilance database, VigiBase

•         To support regulatory decision-making by CDSCO with evidence-based safety information

Since its launch, PvPI has grown from a modest pilot programme into a nationwide network that now encompasses over 250 Adverse Drug Reaction Monitoring Centres located in government hospitals, medical colleges, and healthcare institutions across all states and union territories of India.

How PvPI Works: The Structure of India's ADR Monitoring Network

The National Coordination Centre (NCC)

The IPC serves as the nerve centre of PvPI, responsible for receiving, processing, and analysing ADR reports from across the network of monitoring centres. The NCC maintains India's national pharmacovigilance database, conducts signal detection activities on the accumulated data, and submits India's ADR reports to the WHO's VigiBase through the VigiFlow electronic reporting system. The NCC also provides training and technical support to monitoring centres across the country and publishes periodic safety bulletins for healthcare professionals.

Adverse Drug Reaction Monitoring Centres (AMCs)

AMCs are the primary point of ADR data collection within the PvPI network. Located in hospitals and medical institutions, each AMC is staffed by trained pharmacovigilance professionals — typically pharmacists or physicians with PV training — who are responsible for collecting ADR reports from healthcare professionals and patients within their institution, assessing and coding the reports using MedDRA terminology, and submitting them to the NCC through VigiFlow.

The quality and completeness of reports submitted by AMCs varies significantly depending on the training and resources available at each centre. This is one of the reasons why investing in structured pharmacovigilance education in India is so important — better-trained professionals produce better-quality safety data, which in turn produces more reliable signal detection and more effective regulatory responses.

Healthcare Professional and Patient Reporting

Beyond the formal AMC network, PvPI encourages direct reporting of adverse drug reactions by healthcare professionals and patients through the online ADR reporting portal at adrpvpi.icmr.org.in, the mobile application ADR-PvPI, and the toll-free helpline 1800-180-3024. Increasing the volume and quality of direct reports from frontline healthcare workers remains one of PvPI's most significant ongoing challenges, since under-reporting of ADRs is a universal problem in pharmacovigilance — but one that is particularly pronounced in developing healthcare systems.

CDSCO's Role in Indian Pharmacovigilance

While the IPC manages PvPI's day-to-day operations, the Central Drugs Standard Control Organisation retains regulatory authority over pharmacovigilance in India. CDSCO's pharmacovigilance responsibilities include:

•         Setting the regulatory requirements for pharmacovigilance activities by marketing authorisation holders in India

•         Reviewing safety signals identified by PvPI and determining whether regulatory action is required

•         Issuing drug safety communications, label update requirements, and market withdrawal decisions based on emerging safety evidence

•         Overseeing compliance with pharmacovigilance obligations by pharmaceutical companies operating in India

•         Representing India in international pharmacovigilance forums including the ICH and WHO expert committees

CDSCO's pharmacovigilance regulatory framework is primarily established through the New Drugs and Clinical Trials Rules 2019 and associated guidelines, which set out the obligations of marketing authorisation holders regarding adverse event reporting, periodic safety update reports, risk management plans, and pharmacovigilance system audits.

Key Regulations Governing PV in India

Expedited Reporting Requirements

Marketing authorisation holders in India are required to report fatal or life-threatening unexpected serious adverse reactions to CDSCO within 7 calendar days of becoming aware, with a complete follow-up report submitted within 15 days. Other unexpected serious adverse reactions must be reported within 15 days. These timelines mirror those of the FDA and EMA, reflecting India's increasing alignment with international pharmacovigilance standards.

Periodic Safety Update Reports (PSURs)

Companies holding marketing authorisations in India are required to submit Periodic Safety Update Reports to CDSCO at defined intervals — typically annually for the first two years after approval, and every three years thereafter. PSURs provide a comprehensive summary of the global safety experience with the medicine and evaluate whether the benefit-risk balance remains favourable. CDSCO reviews PSURs as part of its ongoing lifecycle safety monitoring of approved medicines.

Pharmacovigilance System Master File (PSMF)

The PSMF is a detailed document describing the pharmacovigilance system of a marketing authorisation holder — including the organisational structure, qualified person responsible for pharmacovigilance, SOPs, training records, and audit findings. While the PSMF requirement originated in European regulation, CDSCO increasingly expects evidence of a robust pharmacovigilance system from companies seeking new drug approvals in India.

How PvPI Connects to Career Opportunities in Pune

Pune is home to a significant concentration of pharmaceutical companies, CROs, and regulatory consulting firms that work directly within India's pharmacovigilance regulatory framework — submitting ADR reports to CDSCO, preparing PSURs, and maintaining CDSCO-compliant pharmacovigilance systems. For professionals trained in Indian regulatory requirements alongside global PV standards, the career opportunities in Pune's pharmaceutical ecosystem are substantial and growing.

A structured Pharmacovigilance Course in Pune that dedicates specific attention to PvPI, CDSCO requirements, and the practical workflows of Indian pharmacovigilance — in addition to global frameworks like ICH E2A and EMA guidelines — produces graduates who can contribute immediately to both domestic and internationally focused PV roles.

Challenges and the Future of Indian Pharmacovigilance

Despite the significant progress made since 2010, India's pharmacovigilance system still faces important challenges. ADR under-reporting remains widespread — studies suggest that the vast majority of adverse drug reactions in India go unreported. Awareness among healthcare professionals and patients about the importance and mechanisms of ADR reporting is still limited in many parts of the country. And the capacity of AMCs varies enormously depending on institutional resources and the availability of trained personnel.

Addressing these challenges requires a sustained investment in pharmacovigilance education and training — at medical colleges, in hospital pharmacy departments, and through professional development programmes. As India's pharmaceutical industry continues to grow and internationalise, the expectations placed on its pharmacovigilance infrastructure will only increase. The professionals who will lead that improvement are those being trained today.

Conclusion: India's PV Landscape is an Opportunity

Understanding India's pharmacovigilance system — PvPI, CDSCO, the AMC network, and the evolving regulatory framework — is not just academic knowledge for professionals working in this country. It is a genuine competitive advantage, because it means you understand the specific regulatory environment within which Indian pharmaceutical companies and CROs operate every day.

For students in Maharashtra who want to build that advantage from the ground up, choosing a Clinical Research Institute in Pune that integrates Indian pharmacovigilance regulation alongside global standards — covering both the practical workflows of ICSR processing and the strategic landscape of CDSCO compliance — provides the most relevant, career-ready training available in the region today.